Skip to main content

Table 5 Summary of best spleen response and symptom score change from baseline in phase 2 (efficacy evaluable population)a

From: Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies

Endpoint

Patients achieving endpoint, n/N (%)

95% CI

At week 24 visit

Up to week 24 visit

At end of treatment

Up to end of treatment

≥35% spleen volume reduction by MRI

4/17 (23.5)

5/23 (21.7)

4/23 (17.4)

7/23 (30.4)

95% CI 6.8–49.9

95% CI 5.0–38.8

≥50% spleen length reduction by physical examination

9/19 (47.4)

12/31 (38.7)

9/31 (29.0)

12/31 (38.7)

95% CI 24.4–71.1

95% CI 14.2–48.0

≥50% reduction in MF Quality of Life and Symptom Assessment total symptom score

7/18 (38.9)

12/29 (41.4)

4/29 (13.8)

12/29 (41.4)

  1. aPatients included in the efficacy evaluable population are those who had both a non-missing baseline measurement and post-baseline measurement at or through the time point specified
  2. MRI magnetic resonance imaging